Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Atlas Venture Life Science Advisors, LLC (CIK 1917529) reported $790.0M across 6 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: KYMR ($381.3M, 48.26%), DYN ($165.5M, 20.95%), SION ($120.1M, 15.20%), IRON ($96.8M, 12.25%), QTTB ($13.4M, 1.70%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | $381.3M | 48.26% | 4.6M | Trimmed |
| 2 | DYN | Dyne Therapeutics, Inc. | $165.5M | 20.95% | 9.1M | Hold |
| 3 | SION | Sionna Therapeutics, Inc. | $120.1M | 15.20% | 3.0M | Hold |
| 4 | IRON | Disc Medicine, Inc. | $96.8M | 12.25% | 1.5M | Hold |
| 5 | QTTB | Q32 Bio, Inc. | $13.4M | 1.70% | 2.1M | Hold |
| 6 | KRRO | Korro Bio, Inc. | $12.9M | 1.63% | 1.1M | Hold |
| 7 | DAWN | Day One Biopharmaceuticals, Inc. | $0 | 0.00% | 0 | Exited |
| 8 | GBIO | Generation Bio, Co. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31